Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures
- PMID: 28175979
- PMCID: PMC5392413
- DOI: 10.1007/s00198-016-3894-y
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures
Abstract
This narrative review considers the key challenges facing healthcare professionals and policymakers responsible for providing care to populations in relation to bone health. These challenges broadly fall into four distinct themes: (1) case finding and management of individuals at high risk of fracture, (2) public awareness of osteoporosis and fragility fractures, (3) reimbursement and health system policy and (4) epidemiology of fracture in the developing world. Findings from cohort studies, randomised controlled trials, systematic reviews and meta-analyses, in addition to current clinical guidelines, position papers and national and international audits, are summarised, with the intention of providing a prioritised approach to delivery of optimal bone health for all. Systematic approaches to case-finding individuals who are at high risk of sustaining fragility fractures are described. These include strategies and models of care intended to improve case finding for individuals who have sustained fragility fractures, those undergoing treatment with medicines which have an adverse effect on bone health and people who have diseases, whereby bone loss and, consequently, fragility fractures are a common comorbidity. Approaches to deliver primary fracture prevention in a clinically effective and cost-effective manner are also explored. Public awareness of osteoporosis is low worldwide. If older people are to be more pro-active in the management of their bone health, that needs to change. Effective disease awareness campaigns have been implemented in some countries but need to be undertaken in many more. A major need exists to improve awareness of the risk that osteoporosis poses to individuals who have initiated treatment, with the intention of improving adherence in the long term. A multisector effort is also required to support patients and their clinicians to have meaningful discussions concerning the risk-benefit ratio of osteoporosis treatment. With regard to prioritisation of fragility fracture prevention in national policy, there is much to be done. In the developing world, robust epidemiological estimates of fracture incidence are required to inform policy development. As the aging of the baby boomer generation is upon us, this review provides a comprehensive analysis of how bone health can be improved worldwide for all.
Keywords: Case Finding; Disease Awareness; Fragility Fracture; Osteoporosis; Policy; Primary Prevention; Prioritisation; Secondary Prevention.
Conflict of interest statement
BD-H – none for this submission
CC has received consultancy and honoraria from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB.
DDP – none for this submission.
EVM – none for this submission.
JAK and PJM have undertaken consultancy for governments, national osteoporosis societies, healthcare professional organisations and private sector companies relating to systematic approaches to fragility fracture care and prevention.
JYR has no disclosures related to this work, and has received consultancy, lecture fees and grant support from Amgen, Analis, Asahi Kasei, Boehringer, Bristol Myers Squibb, Chiltern, Danone, Ebewee Pharma, Endocyte, Galapagos, GlaxoSmithKline, IBSA-Genevrier, Lilly, Merck Sharp and Dohme, Merckle, Negma, Novartis, NovoNordisk, NPS, Nycomed-Takeda, Organon, Pfizer, PharmEvo, Radius Health, Roche, Rottapharm, Servier, Teijin, Teva, Theramex, Therabel, UCB, Will Pharma, Wyeth, Zodiac.
NCWH has no disclosures related to this work, and has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare and Internis Pharma.
PJM serves as a consultant to the International Osteoporosis Foundation and received remuneration for his contribution to this manuscript.
RR has received honoraria for participation in Advisory boards or speaker bureau fees from Danone, Labatec, Nestlé, and ObsEva.
Figures


Similar articles
-
Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.J Bone Joint Surg Am. 2014 Apr 2;96(7):e52. doi: 10.2106/JBJS.L.01781. J Bone Joint Surg Am. 2014. PMID: 24695929
-
Quality Improvement Initiatives in Fragility Fracture Care and Prevention.Curr Osteoporos Rep. 2019 Dec;17(6):510-520. doi: 10.1007/s11914-019-00544-8. Curr Osteoporos Rep. 2019. PMID: 31734907 Review.
-
Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.Health Technol Assess. 2024 Apr;28(21):1-169. doi: 10.3310/WYPF0472. Health Technol Assess. 2024. PMID: 38634483 Free PMC article.
-
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.Health Technol Assess. 2020 Jun;24(29):1-314. doi: 10.3310/hta24290. Health Technol Assess. 2020. PMID: 32588816 Free PMC article.
-
General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal.Curr Osteoporos Rep. 2020 Feb;18(1):38-46. doi: 10.1007/s11914-020-00566-7. Curr Osteoporos Rep. 2020. PMID: 32103393 Free PMC article. Review.
Cited by
-
Multidisciplinary expert consensus on secondary fracture prevention in Spain.Arch Osteoporos. 2021 Feb 27;16(1):48. doi: 10.1007/s11657-021-00878-w. Arch Osteoporos. 2021. PMID: 33641008 Free PMC article.
-
Real-world effectiveness of osteoporosis treatments in Germany.Arch Osteoporos. 2022 Aug 31;17(1):119. doi: 10.1007/s11657-022-01156-z. Arch Osteoporos. 2022. PMID: 36044096 Free PMC article.
-
Proximal Femoral Fractures in the Elderly: A Few Things to Know, and Some to Forget.Medicina (Kaunas). 2022 Sep 20;58(10):1314. doi: 10.3390/medicina58101314. Medicina (Kaunas). 2022. PMID: 36295475 Free PMC article. Review.
-
Comparison of morbidity and mortality of hip and vertebral fragility fractures: Which one has the highest burden?Osteoporos Sarcopenia. 2020 Sep;6(3):146-150. doi: 10.1016/j.afos.2020.07.002. Epub 2020 Aug 8. Osteoporos Sarcopenia. 2020. PMID: 33102809 Free PMC article.
-
Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.Osteoporos Int. 2019 Sep;30(9):1745-1754. doi: 10.1007/s00198-019-05064-w. Epub 2019 Jul 3. Osteoporos Int. 2019. PMID: 31270592
References
-
- Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57. - PMC - PubMed
-
- Gallagher JC, Melton LJ, Riggs BL, Bergstrath E. Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop Relat Res. 1980:163–171. - PubMed
-
- Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J. Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int. 2003;14:780–784. - PubMed
-
- McLellan A, Reid D, Forbes K, Reid R, Campbell C, Gregori A, Raby N, Simpson A. Effectiveness of Strategies for the Secondary Prevention of Osteoporotic Fractures in Scotland (CEPS 99/03) NHS Quality Improvement Scotland; 2004.
-
- Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007;461:226–230. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous